NCT05514132 2026-03-09A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid TumoursAstraZenecaPhase 1 Active not recruiting14 enrolled